(Reuters Health)—Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds. Drug manufacturers are also less likely to disclose serious adverse events within this window when patient deaths…

T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease
Researchers in the U.K. have discovered that manipulating T cells to exhaustion in a targeted way may lead to new treatments and predictors for various types of autoimmune diseases…
Some Public Hospitals Win, Others Lose with Obamacare
SAN FRANCISCO (Reuters)—A year and a half after the Affordable Care Act brought widespread reforms to the U.S. healthcare system, Chicago’s Cook County Health & Hospitals System has made its first profit in 180 years. Seven hundred miles south, the fortunes of Atlanta’s primary public hospital, Grady Health System, haven’t improved, and it remains as…
Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents
NEW YORK (Reuters Health)—Various organizations recommend dozens of screening and monitoring tests for patients with psoriasis or psoriatic arthritis who are using systemic biologic agents, despite sparse evidence to support any of them. “At a population level, these medications have proven to be very safe and the evidence does not support such extensive and frequent…
Anthem to Buy Cigna to Create Biggest U.S. Health Insurer
(Reuters)—Anthem Inc. said on Friday it would buy Cigna Corp. in a deal valued at $54.2 billion, creating the largest U.S. health insurer by membership. The deal—the biggest ever in the health insurance industry—comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion and is part of an industry-wide consolidation following…

Most Rheumatologists Want FDA to Better Regulate Biosimilars
In a survey, the Coalition of State Rheumatology Organizations found a consensus among rheumatologists that the FDA should increase safety for biosimilar therapies via naming and labeling regulations…
Main Fund for U.S. Medicare Program to Run Out of Money in 2030
WASHINGTON (Reuters)—A slowdown in healthcare spending has shored up the funding outlook for the federal program that pays elderly Americans’ hospital bills, trustees of the program said on Wednesday. The Medicare program’s trust fund for hospital care will run out of money in 2030 the trustees said in a report. That was the same year…

Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.
Americans Want Medicare to Help Negotiate Down Drug Prices
NEW YORK (Reuters)—A vast majority of Americans say the Medicare health program for the elderly should be able to negotiate with drug companies to set lower medication prices, a practice currently prohibited by law, according to a survey released on Friday. The poll conducted by the Kaiser Family Foundation found that 87% of people surveyed…
Did Reports of Side Effects Contribute to Drop in Bone Drug Use?
(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…
- « Previous Page
- 1
- …
- 570
- 571
- 572
- 573
- 574
- …
- 814
- Next Page »